CClinicalTrials.gg
Active, not recruitingNCT07560202ThrombosisUpdated May 1, 2026

Portal Vein Thrombosis in Liver Cirrhosis: Clinical Characteristics, Radiological Patterns, and Predictors

An observational study in Liver Cirrhosis and Portal Vein Thrombosis, sponsored by Elham Ahmed Hassan. Active, not recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Elham Ahmed Hassan · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
240
Ages
18 Years and older
Sex
All
01

Study summary

Portal vein thrombosis (PVT) is a common complication in patients with liver cirrhosis and is associated with increased morbidity due to worsening portal hypertension and hepatic decompensation. The clinical presentation and radiological patterns of PVT vary widely, and the factors predicting its development remain incompletely understood.

This observational study will include adult patients (≥18 years) with established liver cirrhosis who are admitted to the Department of Gastroenterology and Tropical Medicine, Al-Rajhi Liver Hospital, Assiut University. Eligible participants will undergo routine screening for PVT using Doppler ultrasonography, with confirmation by contrast-enhanced computed tomography when indicated.

The study aims to evaluate the clinical characteristics, laboratory parameters, and radiological features of PVT. Cases of PVT will be classified according to extent (partial or complete) and anatomical location (main portal vein, right branch, left branch, or combined involvement). Clinical and laboratory data will be analyzed to identify potential predictors associated with the development and severity of PVT.

The findings of this study are expected to improve understanding of the risk factors and radiological patterns of PVT in cirrhotic patients, contributing to better risk stratification and clinical management.

02

Conditions studied

  • Liver Cirrhosis
  • Portal Vein Thrombosis

Browse trials for

Keywords

  • Portal vein thrombosis
  • liver cirrhosis
  • D-dimer
03

In context

Liver Cirrhosis

1,642 studies on the registry are indexed under Liver Cirrhosis; 358 are open to participants now.

This study's enrollment of 240 is above the median of 151 across 587 observational studies indexed under Liver Cirrhosis.

Browse Liver Cirrhosis studies →

Lead sponsor

Elham Ahmed Hassan is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with liver cirrhosis

Inclusion criteria

  • Adult patients with liver cirrhosis

Exclusion criteria

Exclusion Criteria:

  • Patients with non-hepatic hemostatic disorders, active bacterial sepsis, renal dysfunction, peripheral or hepatic venous thrombosis, recent splenectomy, liver transplantation, antiplatelet or anticoagulant therapy or contraceptive pills were excluded.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
240 participants (actual)
Patient registry
No

Groups and cohorts

  • Group 1 (Patients): with PVT, Group 2 (Controls): without PVT

    Diagnostic Test: Abdominal US, Doppler US and abdominal multi-slice computed tomography (MSCT) with contrast was performed

Interventions

  • Diagnostic testAbdominal US, Doppler US and abdominal multi-slice computed tomography (MSCT) with contrast was performed

    to assess portal circulation, portosystemic collaterals, the presence of PVT, ascites and HCC.

06

What researchers measure

Primary outcomes

  1. Prevalence of Portal Vein Thrombosis (PVT)

    Proportion of cirrhotic patients diagnosed with portal vein thrombosis based on Doppler ultrasonography with confirmation by contrast-enhanced CT when indicated.

    Time frame: At baseline (during study enrollment period)

  2. Predictors of Portal Vein Thrombosis

    Identification of clinical, laboratory, and radiological factors associated with the presence of PVT in cirrhotic patients

    Time frame: Baseline assessment

Secondary outcomes

  1. Radiological Pattern of PVT

    Distribution of portal vein thrombosis according to: Extent (partial vs complete) Anatomical location (main portal vein, right branch, left branch, or combined involvement)

    Time frame: At time of PVT diagnosis

  2. Association Between PVT Type and Clinical Parameters

    Correlation between type of PVT (partial vs complete) and clinical/laboratory characteristics of patients.

    Time frame: At time of diagnosis

07

Study locations

1 site
  • Assiut University Hospital
    Asyut, 71515, Egypt
08

References and documents

Individual participant data

Plan to share: No — I do not have specific consent from participants to share individual-level data.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07560202
Lead sponsor
Elham Ahmed Hassan
Responsible party
Elham Ahmed Hassan (Professor of Gastroenterology and Tropical Medicine, Assiut University) — Sponsor-investigator
First posted
May 1, 2026
Start date
Jun 1, 2025
Primary completion
Jan 1, 2026
Completion
May 1, 2026 (estimated)
Last update
May 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion